Wanfu Bio, UW Genetics, Jiu'an Medical, Daan Genetics.
1.? Wanfu Biological (300482): 20 February disclosure, the company's new product new coronavirus (2019-nCoV) antibody detection kit (colloidal gold method) through the State Drug Administration emergency approval, formally obtained the medical device registration certificate, to become the first batch of new coronavirus antibody on-site rapid test reagents formally approved for listing.
2.? UW Genetics (300676): The company has a virus detection product, SARS coronavirus IgM antibody detection kit.
20 February disclosure, the company's new coronavirus detection kits and analysis software through the State Drug Administration this emergency approval process, becoming one of the first officially approved to market the test products to combat the coronavirus epidemic.
March 20, 2020, the new coronavirus nucleic acid test kit was awarded the European Union Free Sale Certificate, as well as the launch of commercial sales of the new coronavirus nucleic acid test kit in the U.S. clinical market.
3.? Jiuan Medical (002432): The company's new crown antigen home self-test OTC kit products have begun to be sold locally by its subsidiary iHealth USA to both the C-end and the B-end at the same time, and the company is actively approaching and following up on the orders of customers from various parties.
4.? Daan Gene (002030): The company's project "R&D of a new SARS coronavirus PCR fluorescence detection kit" also won the second prize for scientific and technological progress in Guangzhou.
January 20, the company disclosed that it has developed a nucleic acid kit for the new coronary virus, and has obtained a medical device registration certificate for the new coronary virus nucleic acid detection kit.
In May 20, the company's novel coronavirus 2019-nCoV nucleic acid test kit (fluorescent PCR method) product was included as the World Health Organization emergency use list.
Antigen test sales channels
Yifeng Pharmacy (603939): a large pharmaceutical chain of private enterprises, mainly in the central and southern regions (accounting for 84.13% of the share, covering Hunan, Shanghai, Jiangsu, etc.); 2020 the company's 4644 directly-managed chain of stores, has been obtained various types of " Medical insurance designated retail pharmacy" qualification of 3077 pharmacies, accounting for 79.82% of the company's total number of stores.
Dasanlin (603233): South China's leading pharmaceutical retailer, mainly engaged in Chinese and Western patent medicines, health care products, medical equipment and other commodities direct chain retail business; 17 years of national retail sales ranked fifth (8.31 billion); 17 years of the number of stores 3146, accounting for 70% of the Guangdong region.